Experimental studies have revealed that simvastatin ameliorates renal pathology by activating the farnesoid X receptor and Nrf2/HO-1 signaling axis, thereby attenuating oxidative damage, inflammatory responses, and apoptotic pathways in DKD [165]. Here, HMOX1 is linked to diabetic kidney disease.